Short Interest in Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Decreases By 45.5%

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) saw a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 4,200 shares, a decrease of 45.5% from the November 30th total of 7,700 shares. Based on an average daily volume of 17,600 shares, the short-interest ratio is currently 0.2 days.

Scinai Immunotherapeutics Price Performance

SCNI opened at $3.44 on Friday. Scinai Immunotherapeutics has a 12-month low of $2.23 and a 12-month high of $8.92. The company has a market cap of $2.93 million, a price-to-earnings ratio of -0.01 and a beta of 2.43. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 0.06. The stock has a fifty day simple moving average of $3.37 and a two-hundred day simple moving average of $3.61.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.